Griffin Asset Management Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 83,129 shares of the company’s stock after selling 4,253 shares during the quarter. Johnson & Johnson accounts for 1.4% of Griffin Asset Management Inc.’s holdings, making the stock its 16th largest position. Griffin Asset Management Inc.’s holdings in Johnson & Johnson were worth $12,022,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC lifted its position in shares of Johnson & Johnson by 20,130.0% in the 3rd quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock worth $559,832,000 after acquiring an additional 3,437,397 shares during the period. Janus Henderson Group PLC raised its stake in shares of Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after purchasing an additional 2,356,359 shares in the last quarter. Franklin Resources Inc. boosted its stake in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after buying an additional 1,729,281 shares in the last quarter. Holocene Advisors LP bought a new stake in Johnson & Johnson in the 3rd quarter valued at $225,040,000. Finally, FMR LLC lifted its holdings in shares of Johnson & Johnson by 7.4% during the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after acquiring an additional 1,265,748 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Bank of America dropped their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Leerink Partners reduced their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Raymond James dropped their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.44.
Johnson & Johnson Price Performance
Johnson & Johnson stock opened at $152.78 on Friday. The business’s 50-day simple moving average is $147.73 and its 200 day simple moving average is $156.10. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market cap of $367.82 billion, a price-to-earnings ratio of 22.97, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.29 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.25%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.
Insider Transactions at Johnson & Johnson
In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
- Five stocks we like better than Johnson & Johnson
- Health Care Stocks Explained: Why You Might Want to Invest
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- The How and Why of Investing in Gold Stocks
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What is the Hang Seng index?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.